Basiliximab, previously referred to as CHI 621 and possessing the molecular identifier 179045-86-4, represents a antibody agent utilized primarily in avoiding acute rejection following organ transplantation . This humanized antibody specifically targets the interleukin-2 (IL-2) site, effectively hindering IL-2 pathway and subsequently reducing the